Alessandro Cataliotti
Position: Group leader, Professor
Phone: + 47 2301 6807
Email:

Visit research group page at www.iemr.no

 

Publications 2017

Altara R, Giordano M, Nordén ES, Cataliotti A, Kurdi M, Bajestani SN, Booz GW (2017)
Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction
Front Endocrinol (Lausanne), 8, 160
PubMed 28769873

Giordano M, Ciarambino T, Castellino P, Malatino L, Cataliotti A, Rinaldi L, Paolisso G, Adinolfi LE (2017)
Seasonal variations of hyponatremia in the emergency department: Age-related changes
Am J Emerg Med, 35 (5), 749-752
PubMed 28131601

Giordano M, Ciarambino T, Priore EL, Castellino P, Malatino L, Cataliotti A, Paolisso G, Adinolfi LE (2017)
Serum sodium correction rate and the outcome in severe hyponatremia
Am J Emerg Med, 35 (11), 1691-1694
PubMed 28600073

Holditch SJ, Schreiber CA, Harris PC, LaRusso NF, Ramirez-Alvarado M, Cataliotti A, Torres VE, Ikeda Y (2017)
B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease
Kidney Int, 92 (3), 657-668
PubMed 28416225

Publications 2016

Buonacera A, Boukhris M, Tomasello SD, Campagna A, Cilia C, Tripepi G, Di Marca S, Terranova V, Pisano M, Mastrosimone G, Galassi AR, Stancanelli B, Cataliotti A, Malatino L (2016)
Impact of left ventricular remodeling and renal function on 24h-ECG recordings and cardiovascular outcome in elderly hypertensive patients
Eur J Intern Med, 29, 71-7
PubMed 26781517

Publications 2015

Bellavia D, Cataliotti A, Clemenza F, Baravoglia CH, Luca A, Traina M, Gridelli B, Bertani T, Burnett JC, Scardulla C (2015)
Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study
PLoS One, 10 (11), e0142103
PubMed 26556804

Holditch SJ, Schreiber CA, Nini R, Tonne JM, Peng KW, Geurts A, Jacob HJ, Burnett JC, Cataliotti A, Ikeda Y (2015)
B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension
Hypertension, 66 (1), 199-210
PubMed 26063669

Røsjø H, Dahl MB, Jørgensen M, Røysland R, Brynildsen J, Cataliotti A, Christensen G, Høiseth AD, Hagve TA, Omland T (2015)
Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study
Clin Chem, 61 (8), 1087-97
PubMed 26056354

Publications 2014

Aspelin T, Eriksen M, Ilebekk A, Cataliotti A, Carlson CR, Lyberg T (2014)
β-blockade abolishes the augmented cardiac tPA release induced by transactivation of heterodimerised bradykinin receptor-2 and β2-adrenergic receptor in vivo
Thromb Haemost, 112 (5), 951-9
PubMed 25078038

Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessì-Fulgheri P, Sarzani R, Burnett JC (2014)
Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease
Hypertension, 65 (1), 45-53
PubMed 25368032

Giordano M, Ciarambino T, Castellino P, Cataliotti A, Malatino L, Ferrara N, Politi C, Paolisso G (2014)
Long-term effects of moderate protein diet on renal function and low-grade inflammation in older adults with type 2 diabetes and chronic kidney disease
Nutrition, 30 (9), 1045-9
PubMed 24993749

McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC (2014)
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics
J Am Heart Assoc, 3 (1), e000206
PubMed 24385449

Tonne JM, Holditch SJ, Oehler EA, Schreiber CA, Ikeda Y, Cataliotti A (2014)
Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease
Aging (Albany NY), 6 (4), 311-9
PubMed 24799459

Publications 2013

Ichiki T, Izumi R, Cataliotti A, Larsen AM, Sandberg SM, Burnett JC (2013)
Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis
Peptides, 48, 21-6
PubMed 23927843

Publications 2012

Cataliotti A, Costello-Boerrigter LC, Chen HH, Textor SC, Burnett JC (2012)
Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension
Mayo Clin Proc, 87 (4), 413-5
PubMed 22469356

Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC (2012)
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
J Am Coll Cardiol, 60 (22), 2305-12
PubMed 23122795

Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J, Cataliotti A (2012)
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP
J Am Coll Cardiol, 60 (16), 1558-65
PubMed 23058313

Malatino LS, Cataliotti A, Stancanelli B, Zoccali C (2012)
Hepatocyte growth factor and cardiomyopathy in dialysis patients
Hypertension, 60 (3), e24; author reply e25-6
PubMed 22868387

Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC (2012)
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
Eur Heart J, 34 (12), 886-893c
PubMed 22942338

Publications 2011

Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett JC (2011)
A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community
J Am Coll Cardiol, 58 (6), 629-36
PubMed 21798427

Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, Burnett JC, Ikeda Y (2011)
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats
Circulation, 123 (12), 1297-305
PubMed 21403100

Macheret F, Boerrigter G, McKie P, Costello-Boerrigter L, Lahr B, Heublein D, Sandberg S, Ikeda Y, Cataliotti A, Bailey K, Rodeheffer R, Burnett JC (2011)
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction
J Am Coll Cardiol, 57 (12), 1386-95
PubMed 21414536

Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC (2011)
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
Am J Physiol Regul Integr Comp Physiol, 302 (2), R292-9
PubMed 22071162

McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC (2011)
Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study
Mayo Clin Proc, 86 (12), 1154-60
PubMed 22134933

Sangaralingham SJ, Heublein DM, Grande JP, Cataliotti A, Rule AD, McKie PM, Martin FL, Burnett JC (2011)
Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging
Am J Physiol Renal Physiol, 301 (5), F943-52
PubMed 21865266

Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, Macheret F, Huntley BK, Burnett JC, Ikeda Y (2011)
Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes
Clin Chem, 57 (6), 864-73
PubMed 21482747

Publications 2010

Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC (2010)
Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure
Circ Heart Fail, 3 (3), 412-9
PubMed 20176717

McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T, Burnett JC (2010)
A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
Hypertension, 56 (6), 1152-9
PubMed 20975033

McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC (2010)
The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects
J Am Coll Cardiol, 55 (19), 2140-7
PubMed 20447539

Publications 2009

Boerrigter G, Costello-Boerrigter LC, Harty GJ, Huntley BK, Cataliotti A, Lapp H, Burnett JC (2009)
B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity
Am J Physiol Regul Integr Comp Physiol, 296 (6), R1744-50
PubMed 19386989

Chen HH, Cataliotti A, Schirger JA, Martin FL, Harstad LK, Burnett JC (2009)
Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure
J Am Coll Cardiol, 53 (15), 1302-8
PubMed 19358945

McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett JC (2009)
A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions
J Am Coll Cardiol, 54 (11), 1024-32
PubMed 19729120

Stancanelli B, Malatino LS, Cataliotti A, Bellanuova I, Mallamaci F, Tripepi G, Benedetto FA, Leonardis D, Fatuzzo P, Rapisarda F, Zoccali C (2009)
Soluble e-selectin is an inverse and independent predictor of left ventricular wall thickness in end-stage renal disease patients
Nephron Clin Pract, 114 (1), c74-80
PubMed 19851079

Publications 2008

Cataliotti A, Chen HH, Schirger JA, Martin FL, Boerrigter G, Costello-Boerrigter LC, James KD, Polowy K, Miller MA, Malkar NB, Bailey KR, Burnett JC (2008)
Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension
Circulation, 118 (17), 1729-36
PubMed 18838565

Hawkridge AM, Muddiman DC, Hebulein DM, Cataliotti A, Burnett JC (2008)
Effect of plasma protein depletion on BNP-32 recovery
Clin Chem, 54 (5), 933-4
PubMed 18443186

Martin FL, Chen HH, Cataliotti A, Burnett JC (2008)
Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators
Rev Cardiovasc Med, 9 (1), 39-45
PubMed 18418308

Martin FL, Chen HH, Cataliotti A, Burnett JC (2008)
B-type natriuretic peptide: beyond a diagnostic
Heart Fail Clin, 4 (4), 449-54
PubMed 18760756

Publications 2007

Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC (2007)
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure
Hypertension, 49 (5), 1128-33
PubMed 17325237

Cataliotti A, Chen HH, James KD, Burnett JC (2007)
Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease
Trends Cardiovasc Med, 17 (1), 10-4
PubMed 17210472

Costello-Boerrigter LC, Boerrigter G, Harty GJ, Cataliotti A, Redfield MM, Burnett JC (2007)
Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction
Hypertension, 50 (3), 481-8
PubMed 17635858

Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC (2007)
Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide
Hypertension, 49 (5), 1114-9
PubMed 17372040

Publications 2006

Belluardo P, Cataliotti A, Bonaiuto L, Giuffrè E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS (2006)
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
Am J Physiol Heart Circ Physiol, 291 (4), H1529-35
PubMed 16648193

Cataliotti A, Chen HH, Redfield MM, Burnett JC (2006)
Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications
Heart Fail Clin, 2 (3), 269-76
PubMed 17386896

Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC (2006)
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure
J Am Soc Nephrol, 17 (10), 2742-7
PubMed 16928803

Chen HH, Schirger JA, Cataliotti A, Burnett JC (2006)
Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
Eur J Heart Fail, 8 (7), 681-6
PubMed 16459135

Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Y, Burnett JC (2006)
BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors
J Cell Physiol, 209 (3), 943-9
PubMed 16986166

McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC (2006)
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure
Hypertension, 47 (5), 874-80
PubMed 16585413

Publications 2005

Cataliotti A, Burnett JC (2005)
Natriuretic peptides: novel therapeutic targets in heart failure
J Investig Med, 53 (7), 378-84
PubMed 16297366

Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC (2005)
Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure
Circulation, 112 (6), 836-40
PubMed 16061734

Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC (2005)
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
Proc Natl Acad Sci U S A, 102 (48), 17442-7
PubMed 16293687

James KD, Cataliotti A, Schirger JA, Plonka S, Burnett JC (2005)
Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide
Curr Med Chem, 12 (12), 1439-47
PubMed 15974994

Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC (2005)
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure
Kidney Int, 67 (5), 1723-30
PubMed 15840018

Publications 2004

Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC (2004)
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure
Circulation, 109 (13), 1680-5
PubMed 15023890

Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC (2004)
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
Am J Physiol Regul Integr Comp Physiol, 288 (5), R1093-7
PubMed 15627648

Panuccio V, Tripepi R, Tripepi G, Mallamaci F, Benedetto FA, Cataliotti A, Bellanuova I, Giacone G, Malatino LS, Zoccali C (2004)
Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients
Am J Kidney Dis, 43 (3), 479-84
PubMed 14981606

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS (2004)
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients
J Am Soc Nephrol, 15 (4), 1029-37
PubMed 15034106

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS (2004)
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression
Kidney Int, 65 (4), 1492-8
PubMed 15086493

Publications 2003

Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC (2003)
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure
Circulation, 107 (5), 686-9
PubMed 12578869

Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC (2003)
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure
Am J Physiol Renal Physiol, 284 (5), F1115-9
PubMed 12676739

Jougasaki M, Leskinen H, Larsen AM, Cataliotti A, Chen HH, Burnett JC (2003)
Leukemia inhibitory factor is augmented in the heart in experimental heart failure
Eur J Heart Fail, 5 (2), 137-45
PubMed 12644003

Jougasaki M, Leskinen H, Larsen AM, Luchner A, Cataliotti A, Tachibana I, Burnett JC (2003)
Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure
Peptides, 24 (6), 889-92
PubMed 12948841

Malatino LS, Cataliotti A, Benedetto FA, Stancanelli B, Bellanuova I, Belluardo P, Bonaiuto L, Tripepi G, Mallamaci F, Castellino P, Zoccali C (2003)
Hepatocyte growth factor and left ventricular geometry in end-stage renal disease
Hypertension, 41 (1), 88-92
PubMed 12511535

Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC (2003)
Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention
Circulation, 109 (2), 249-54
PubMed 14691038

Tsuruda T, Jougasaki M, Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lee SC, Salz-Gilman L, Nordstrom LJ, McGregor CG, Burnett JC (2003)
Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart
Regul Pept, 112 (1-3), 161-6
PubMed 12667638

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS (2003)
Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease
J Hypertens, 21 (7), 1355-62
PubMed 12817184

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Iellamo D, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS (2003)
Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease
J Am Soc Nephrol, 14 (10), 2611-7
PubMed 14514739

Publications 2002

Castellino P, Cataliotti A (2002)
Changes of protein kinetics in nephrotic patients
Curr Opin Clin Nutr Metab Care, 5 (1), 51-4
PubMed 11790950

Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello LC, Tsuruda T, Lee SC, Malatino LS, Burnett JC (2002)
Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure
Circulation, 105 (5), 639-44
PubMed 11827932

Cataliotti A, Giordano M, De Pascale E, Giordano G, Castellino P, Jougasaki M, Costello LC, Boerrigter G, Tsuruda T, Belluardo P, Lee SC, Huntley B, Sandberg S, Malatino LS, Burnett JC (2002)
CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome
Am J Physiol Renal Physiol, 283 (3), F464-72
PubMed 12167597

Jougasaki M, Larsen AM, Cataliotti A, Christiansen DC, Burnett JC (2002)
Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells
Peptides, 23 (8), 1441-7
PubMed 12182945

Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A, CREED Investigators (2002)
Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients
Kidney Int, 61 (2), 609-14
PubMed 11849403

Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC (2002)
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases
Circ Res, 91 (12), 1127-34
PubMed 12480813

Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC (2002)
Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor
Circ Res, 90 (2), 128-34
PubMed 11834704

Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger R, CREED Investigators (2002)
Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients
Kidney Int, 62 (1), 339-45
PubMed 12081596

Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS (2002)
Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease
Circulation, 105 (11), 1354-9
PubMed 11901048

Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS, CREED investigators (2002)
Norepinephrine and concentric hypertrophy in patients with end-stage renal disease
Hypertension, 40 (1), 41-6
PubMed 12105136